GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jul 7, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on July 7, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not indicate any new material risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker
- 31¼ pence (dollar_amount) — Nominal value of ordinary shares
FAQ
What was the date of the transaction?
The filing indicates the report is for the month of July 2025 and mentions 'Date of purchase' but does not specify a particular date within the provided text.
How many shares did GSK plc purchase?
The filing states that GSK plc purchased 'the following number of the Company's ordinary shares' but the specific number is not detailed in the provided text.
What was the total cost of the share repurchase?
The filing does not disclose the total dollar amount spent on the share repurchase.
Who acted as GSK's stockbroker for this transaction?
Merrill Lynch International acted as GSK's corporate stockbroker for the purchase of its own shares.
What is the nominal value of GSK's ordinary shares?
The nominal value of GSK's ordinary shares is 31¼ pence each.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 7, 2025 regarding GSK plc (GLAXF).